search
Back to results

Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer

Primary Purpose

Breast Cancer

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ultrasound tomography
magnetic resonance imaging
Sponsored by
Barbara Ann Karmanos Cancer Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Breast Cancer

Eligibility Criteria

18 Years - 89 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Scheduled for mammogram, breast ultrasound and/or breast MRI
  • Breast size less than 22 cm diameter (ring diameter is 22cm)
  • Able to read or understand and provide informed consent
  • Weight < 350lbs (patient bed max weight)
  • Non-pregnant and non-lactating
  • No open breast or chest wounds
  • No active skin infection
  • No serious medical or psychiatric illnesses that would prevent informed consent

Sites / Locations

  • Barbara Ann Karmanos Cancer Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Diagnostic (SoftVue ultrasound tomography)

Arm Description

Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.

Outcomes

Primary Outcome Measures

Evaluation the SoftVue system with respect to spatial resolution, contrast, sound speed resolution, and attenuation resolution
For each type of resolution, observed values will be averaged over slices for each participant and compared to milestone values. The proportion of individuals whose images meet the milestone criteria will be reported with 95% confidence intervals calculated using Wilson's method.

Secondary Outcome Measures

Ability of the system to identify pathological features previously identified by other imaging modalities
The sensitivity of the SoftVue system to identify pathologic features will be estimated with 95% confidence intervals using previous imaging studies as the gold standard.
Percent agreement between SoftVue (ultrasound tomography classification) and MRI (MR Breast Imaging-Reporting and Data System [BIRADS] classification)
Will be calculated along with 95% confidence intervals.
Sound speed as a percentage measure of dense breast tissue
Compare measured sound speed values against known values for the range of tissue types imaged (e.g. fatty breasts should have average sound speeds consistent with known speeds for fatty tissue).

Full Information

First Posted
September 26, 2012
Last Updated
May 24, 2022
Sponsor
Barbara Ann Karmanos Cancer Institute
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT01698658
Brief Title
Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer
Official Title
Clinical Data Collection for Initial Evaluation of SoftVue: a Novel Ultrasound Breast Scanner
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
November 16, 2018 (Actual)
Study Completion Date
November 16, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Barbara Ann Karmanos Cancer Institute
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This clinical trial studies ultrasound tomography using SoftVue in diagnosing women with breast cancer. New diagnostic procedures, such as ultrasound tomography using SoftVue, may help find and diagnose breast cancer.
Detailed Description
PRIMARY OBJECTIVES: I. Determine the in-vivo imaging potential of SoftVue through 3-dimensional (3-D) breast imaging. II. Acquire data for SoftVue evaluation from a cohort of 100 women receiving standard ultrasound (US) evaluation as follow-up to mammographic or palpable abnormalities and construct reflection, sound speed and attenuation images with SoftVue. III. Evaluate the ability of SoftVue to detect dominant breast findings (i.e. major normal landmark architecture) or masses previously identified with standard diagnostic evaluation (palpation, mammography, standard US) using standard clock position and radial distance measurements from the nipple. IV. Conduct tomographic (i.e. slice-by-slice) comparison of SoftVue with magnetic resonance imaging (MRI) findings from a subgroup of 50 patients. OUTLINE: Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
657 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Diagnostic (SoftVue ultrasound tomography)
Arm Type
Experimental
Arm Description
Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.
Intervention Type
Other
Intervention Name(s)
ultrasound tomography
Intervention Description
Undergo ultrasound tomography using SoftVue
Intervention Type
Procedure
Intervention Name(s)
magnetic resonance imaging
Other Intervention Name(s)
MRI, NMR imaging, NMRI, nuclear magnetic resonance imaging
Intervention Description
Undergo MRI of the breast
Primary Outcome Measure Information:
Title
Evaluation the SoftVue system with respect to spatial resolution, contrast, sound speed resolution, and attenuation resolution
Description
For each type of resolution, observed values will be averaged over slices for each participant and compared to milestone values. The proportion of individuals whose images meet the milestone criteria will be reported with 95% confidence intervals calculated using Wilson's method.
Time Frame
At time of procedure
Secondary Outcome Measure Information:
Title
Ability of the system to identify pathological features previously identified by other imaging modalities
Description
The sensitivity of the SoftVue system to identify pathologic features will be estimated with 95% confidence intervals using previous imaging studies as the gold standard.
Time Frame
At time of procedure
Title
Percent agreement between SoftVue (ultrasound tomography classification) and MRI (MR Breast Imaging-Reporting and Data System [BIRADS] classification)
Description
Will be calculated along with 95% confidence intervals.
Time Frame
At time of procedure
Title
Sound speed as a percentage measure of dense breast tissue
Description
Compare measured sound speed values against known values for the range of tissue types imaged (e.g. fatty breasts should have average sound speeds consistent with known speeds for fatty tissue).
Time Frame
At time of procedure

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Scheduled for mammogram, breast ultrasound and/or breast MRI Breast size less than 22 cm diameter (ring diameter is 22cm) Able to read or understand and provide informed consent Weight < 350lbs (patient bed max weight) Non-pregnant and non-lactating No open breast or chest wounds No active skin infection No serious medical or psychiatric illnesses that would prevent informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alit Amit-Yousif, M.D.
Organizational Affiliation
Barbara Ann Karmanos Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Barbara Ann Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer

We'll reach out to this number within 24 hrs